权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Low-Cost Platform Technology for Rapid Isolation of Peripheral Blood Mononuclear Cells

快速分离外周血单个核细胞的低成本平台技术

基本信息

批准号：
10077472
负责人：
Lotien Richard Huang
金额：
$ 27.49万
依托单位：
CG SCIENTIFIC, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10077472
关键词：
Area Autoimmune Diseases Biotechnology Blood Blood Platelets Boston Cell Separation Cell Survival Cells Centrifugation Clinical Clinical Research Communicable Diseases Core Facility Cycloparaffins Dana-Farber Cancer Institute Data Density Gradient Centrifugation Development Devices Disease Engineering Erythrocytes Excision Ficoll Flow Cytometry Force of Gravity General Hospitals Health Human Immune system Immunologist Immunology Label Laboratories Legal patent Malignant Neoplasms Massachusetts Methods Microfluidic Microchips Microfluidics Names Nature Output Pediatric Hospitals Performance Peripheral Blood Mononuclear Cell Phase Phenotype Polymers Population Principal Investigator Publications Recovery Reproducibility Research Research Personnel Running Science Techniques Technology Time Universities Variant artemis base cell injury cell type clinical application commercialization cost cost effective cost effectiveness density design drug discovery graft vs host disease high dimensionality human error improved manufacturability medical schools microfluidic technology new technology novel prototype scale up shear stress success tool vaccine development

项目摘要

Project Summary/Abstract CG Scientific aims to develop a low-cost microfluidic device for rapid isolation of peripheral blood mononuclear cells (PBMCs), based on its patented platform technology named “High Efficiency Deterministic Separation (HEDS).” This Phase I project will focus on PBMCs because they are essential cells used in many areas of scientific and clinical research, including immunology, vaccine development, drug discovery, as well as the study of auto-immune disorder, infectious disease, graft-versus-host disease, and cancer. The current standard method for PBMC isolation is Ficoll density gradient centrifugation. However, the method is difficult to perform, requires substantial hands-on time, and is prone to human error and contamination. Further, it introduces biases and phenotypic changes of the enriched cell population and results in cell loss during multiple wash and centrifugation steps. These drawbacks make the method unsuitable for many applications, especially those that require the results be consistent, accurate, and representative of disease states. To provide a better method that is free from these drawbacks and that is cost-competitive with Ficoll, CG Scientific is developing an easy-to-use device that can isolate PBMCs from 10 ml of blood in 15 minutes, enabled by the HEDS technology. The technology has a unique configuration that allows for efficient density-medium-free isolation of cells and low manufacturing cost. Preliminary data have shown that HEDS can outperform Ficoll density gradient centrifugation and deliver significantly better PBMC recovery, RBC removal, and platelet depletion—with undetectable loss of cell viability—using simply gravity feed. This Phase I project is aimed at demonstrating the two most critical aspects of HEDS—rapid, high-yield PBMC isolation and low manufacturing cost—following 3 Specific Aims: (1) optimize HEDS chip design to further improve cell recovery and scale up throughput, (2) validate optimized chip performance and characterize cellular output using flow cytometry in comparison with Ficoll density gradient centrifugation, and (3) demonstrate plastic HEDS chip manufacturability using soft embossing. The investigator team includes the inventor of the HEDS technology, cell biologists, plastic device manufacturing engineers, and directors of research and clinical laboratories that are regular users of Ficoll. The success of this project will lead to the development of an essential tool that will potentially replace Ficoll density gradient as the standard method for isolating PBMCs and many other important cell types, and make scientific and clinical research in many fields more efficient, reproducible, and cost effective.

项目总结/文摘